Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000261739

Medchemexpress LLC Bet bromodomain inhibitor 1 | 2411226-02-1 | 99.9% | C22H19F2N3O4S | 10MG
SDP

Catalog No. 5000261739
Encompass_Preferred

BET bromodomain inhibitor 1 is an orally active, selective BET family bromodomain inhibitor used in epigenetic and anticancer research. It binds BRD4 with low-nanomolar potency and shows antiproliferative activity in multiple human cancer cell lines.

  • Potent BRD4 inhibition (IC50 = 2.6 nM).
  • Low-nanomolar binding to BET family members (Kd values ~1-3 nM).
  • High purity (≈99.9%) suitable for research applications.
  • Defined molecular formula C22H19F2N3O4S and molecular weight 459.47 g/mol.
  • Demonstrated antiproliferative activity in cancer cell lines.
  • Available in small research pack sizes and as a DMSO stock solution.

Catalog No. 50-002-61739 Supplier Medchemexpress LLC Supplier No. HY13106110MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

BET bromodomain inhibitor 1 is an orally active, selective BET family bromodomain inhibitor used in epigenetic and anticancer research. It binds BRD4 with low-nanomolar potency and shows antiproliferative activity in multiple human cancer cell lines.

  • Potent BRD4 inhibition (IC50 = 2.6 nM).
  • Low-nanomolar binding to BET family members (Kd values ~1-3 nM).
  • High purity (≈99.9%) suitable for research applications.
  • Defined molecular formula C22H19F2N3O4S and molecular weight 459.47 g/mol.
  • Demonstrated antiproliferative activity in cancer cell lines.
  • Available in small research pack sizes and as a DMSO stock solution.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.